| Literature DB >> 22021756 |
Kaare Engkilde1, Jacob P Thyssen, Torkil Menné, Jeanne D Johansen.
Abstract
Background Contact allergy is a prevalent disorder. It is estimated that about 20% of the general population are allergic to one or more of the chemicals that constitute the European baseline patch test panel. While many studies have investigated associations between type I allergic disorders and cancer, few have looked into the association between cancer and contact allergy, a type IV allergy. By linking two clinical databases, the authors investigate the possible association between contact allergy and cancer. Methods Record linkage of two different registers was performed: (1) a tertiary hospital register of dermatitis patients patch tested for contact allergy and (2) a nationwide cancer register (the Danish Cancer Register). After linking the two registers, only cancer subtypes with 40 or more patients registered were included in the analysis. The final associations were evaluated by logistic regression analysis. Results An inverse association between contact allergy and non-melanoma skin- and breast cancer, respectively, was identified in both sexes, and an inverse trend for brain cancer was found in women with contact allergy. Additionally, a positive association between contact allergy and bladder cancer was found. Conclusion The inverse associations support the immunosurveillance hypothesis (ie, individuals with an allergy are less likely to get cancer due to a triggered immune system), while the positive association with bladder cancer could be due to accumulations of chemical metabolites in the bladder. The authors' findings add to the limited knowledge about contact allergy and the risk of cancer.Entities:
Year: 2011 PMID: 22021756 PMCID: PMC3191431 DOI: 10.1136/bmjopen-2011-000084
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Sex-specific distribution of cancer types and contact allergy
| Cancer groups (NORDCAN) | Sex | Total | |||||
| Men | Women | ||||||
| No contact allergy | Contact allergy | Total | No contact allergy | Contact allergy | Total | ||
| Pancreas | 11 | 4 | 15 | 13 | 17 | 30 | 45 |
| 24.4% | 8.9% | 33.3% | 28.9% | 37.8% | 66.7% | 100% | |
| Brain/CNS | 15 | 7 | 22 | 30 | 11 | 41 | 63 |
| 23.8% | 11.1% | 34.9% | 47.6% | 17.5% | 65.1% | 100% | |
| Cervix uteri | NA | NA | NA | 34 | 30 | 64 | 64 |
| 53.1% | 46.9% | 100% | 100% | ||||
| Leukaemia | 27 | 7 | 34 | 24 | 13 | 37 | 71 |
| 38.0% | 9.9% | 47.9% | 33.8% | 18.3% | 52.1% | 100% | |
| Lip, oral cavity and pharynx | 30 | 15 | 45 | 16 | 12 | 28 | 73 |
| 41.1% | 20.5% | 61.6% | 21.9% | 16.4% | 38.4% | 100% | |
| Corpus uteri | NA | NA | NA | 48 | 38 | 86 | 86 |
| 55.8% | 44.2% | 100% | 100% | ||||
| Rectum and anus | 41 | 14 | 55 | 29 | 17 | 46 | 101 |
| 40.6% | 13.9 | 54.5% | 28.7% | 16.8% | 45.5% | 100% | |
| Melanoma of skin | 32 | 11 | 43 | 40 | 21 | 61 | 104 |
| 30.8% | 10.6% | 41.3% | 38.5% | 20.2% | 58.7% | 100% | |
| Prostate | 86 | 36 | 122 | NA | NA | NA | 122 |
| 70.5% | 29.5% | 100% | 100% | ||||
| Colon | 43 | 9 | 52 | 43 | 29 | 72 | 124 |
| 34.7% | 7.3% | 41.9% | 34.7% | 23.4% | 58.1% | 100% | |
| Bladder, etc | 63 | 33 | 96 | 21 | 22 | 43 | 139 |
| 45.3% | 23.7% | 69.1% | 15.1% | 15.8% | 30.9% | 100% | |
| Lung | 83 | 26 | 109 | 41 | 42 | 83 | 192 |
| 43.2% | 13.5% | 56.8% | 21.4% | 21.9% | 43.2% | 100% | |
| Colorectal | 83 | 23 | 106 | 71 | 46 | 117 | 223 |
| 37.2% | 10.3% | 47.5% | 31.8% | 20.6% | 52.5% | 100% | |
| Breast | 0 | 0 | 0 | 248 | 151 | 399 | 399 |
| 62.2% | 37.8% | 100% | 100% | ||||
| Skin, non-melanoma | 203 | 72 | 275 | 284 | 166 | 450 | 725 |
| 28.0% | 9.9% | 37.9% | 39.2% | 22.9% | 62.1% | 100% | |
| All sites but non-melanoma skin cancer | 531 | 209 | 740 | 663 | 452 | 1115 | 1855 |
| 28.6% | 11.3% | 39.9% | 35.7% | 24.4% | 60.1% | 100% | |
| Total (allergy database) | 4519 | 1594 | 6113 | 4471 | 6338 | 10 809 | 16 922 |
| 26.7% | 9.4% | 36.1% | 26.4% | 37.5% | 63.9% | 100% | |
The cancer types are sorted ascendingly according to the total number of patients with the respective cancer type. Only cancer types with ≥40 patients were included in the logistic regression analyses. CNS, central nervous system.
Logistic analysis for the individual cancer group adjusted for age and sex
| Cancer groups (NORDCAN) | p Value | OR (95% CI) |
| Pancreas | 0.184 | 1.50 (0.83 to 2.72) |
| Brain/CNS | 0.159 | 0.66 (0.38 to 1.16) |
| Cervix uteri | 0.503 | 1.18 (0.73 to 1.94) |
| Leukaemia | 0.233 | 0.73 (0.43 to 1.23) |
| Lip, oral cavity and pharynx | 0.496 | 1.18 (0.73 to 1.92) |
| Corpus uteri | 0.797 | 1.06 (0.69 to 1.62) |
| Rectum and anus | 0.470 | 0.85 (0.55 to 1.31) |
| Melanoma of skin | 0.262 | 0.79 (0.51 to 1.20) |
| Prostate | 0.455 | 1.16 (0.78 to 1.73) |
| Colon | 0.215 | 0.78 (0.53 to 1.15) |
| Bladder, etc | 0.039 | 1.44 (1.02 to 2.05) |
| Lung | 0.720 | 1.06 (0.78 to 1.43) |
| Colorectal | 0.187 | 0.82 (0.61 to 1.10) |
| Breast | 0.031 | 0.80 (0.65 to 0.98) |
| Skin, non-melanoma | 0.020 | 0.82 (0.70 to 0.97) |
| All sites but non-melanoma skin cancer | 0.415 | 0.96 (0.86 to 1.06) |
| Final logistic analysis | ||
| Bladder, etc | 0.040 | 1.44 (1.02 to 2.05) |
| Breast | 0.035 | 0.80 (0.65 to 0.98) |
| Skin, non-melanoma | 0.021 | 0.83 (0.70 to 0.97) |
| Brain/CNS | 0.513 | 1.35 (0.55 to 3.33) |
| Brain/CNS×sex | 0.080 | 0.36 (0.12 to 1.13) |
The last six rows are the final analysis outcome with the interaction variable and the significant cancer groups. CNS, central nervous system.